Alger Capital, an investment management company, released its “Alger Small Cap Focus Fund” fourth quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund underperformed the Russell 2000 Growth Index. The Energy and Communication Services sectors contributed to the fund’s relative performance in the quarter, while Consumer Discretionary […]
Needham launched its coverage on ShockWave Medical (SWAV) with a Buy rating on Wednesday, citing an attractive valuation level despite high growth prospects. Read the full story here.
Shockwave Medical (SWAV) said its L6 Peripheral IVL Catheter was now commercially available in the U.S. following clearance by the U.S
Shockwave L⁶ Provides Physicians with Larger-Diameter Catheters to Expand Potential Treatment of Peripheral Vessels Shockwave L⁶ Provides Physicians with Larger-Diameter Catheters to Expand Potential Treatment of Peripheral Vessels
ShockWave Medical Inc. (NASDAQ:SWAV) marked $198.34 per share on Tuesday, up from a previous closing price of $191.90. While ShockWave Medical Inc. has overperformed by 3.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 12.67%, with highs and lows ranging from $320.54 to […]
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for …
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical, Inc. (“Shockwave”) by way of a statutory plan of arrangement (the “Arrangement”) at the special meeting of Shareholders held today (the “Meeting”).
Condition : Coronary Artery Disease Intervention : Device: Shockwave Medical Coronary IVL System Sponsor : Shockwave Medical, Inc. Not yet recruiting
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, its Investor Class fund ARTSX returned 6.27%, Advisor Class fund APDSX posted a return of 6.31%, and Institutional Class fund APHSX returned 6.38%, compared to a […]
As of Tuesday, ShockWave Medical Inc.’s (NASDAQ:SWAV) stock closed at $190.24, up from $189.52 the previous day. While ShockWave Medical Inc. has overperformed by 0.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 8.34%, with highs and lows ranging from $320.54 to $113.36, […]
When a company beats earnings estimates, investors often pile into it. But not all earnings beats are created equal. Twilio (NYSE: TWLO ) announced large layoffs and told analysts to expect bad numbers, then beat them. Microsoft (NASDAQ: MSFT ) showed big gains in the cloud, but it’s losing its biggest franchise in Windows. SunPower (NASDAQ: SPWR ) beat estimates, but not by enough to change the narrative. Sometimes a beat is management gamesmanship. You tell analysts things are going to be horrible so if they’re not so bad you’re a hero. That is what AMC Networks (NASDAQ: AMCX ) did, delivering a loss that wasn’t as bad as expected. Or you can beat estimates while remaining overvalued , as Shopify (NYSE: SHOP ) did. Finding gold in earnings releases means looking at a company’s business prospects, the stability of its model, and the general economy. The companies in this gallery are in a wide variety of industries, but they know what they’re about, they don’t usually make big negative headlines, and they’re all a bet on growth for the U.S. economy.
ShockWave is profitable with good cost controls, unlike many other technology peers that are growing at a breakneck pace. Find out why SWAV stock is a Buy.
In last trading session, ShockWave Medical Inc. (NASDAQ:SWAV) saw 1.47 million shares changing hands with its beta currently measuring 0.97. Company’s recent per share price level of $199.37 trading at $8.13 or 4.25% at ring of the bell on the day assigns it a market valuation of $7.19B. That closing price of SWAV’s stock is … ShockWave Medical Inc. (NASDAQ:SWAV) Is 43.14% Above Its 52-Week Low, But How Long Can It Continue? Read More »
Shockwave Medical tripled Wall Street''s fourth-quarter profitability expectations, leading SWAV stock to surge on Friday.
Shockwave Medical Inc (NASDAQ: SWAV ) reported Q4 FY22 revenue of $144 million , an increase of 71% year-over-year, beating the consensus of $142.60 million, primarily driven by an increase in the purchase volume of C2 catheters in the U.S. and increased adoption of products internationally. The gross margin … Full story available on Benzinga.com
SWAV earnings call for the period ending December 31, 2022.
ShockWave Medical, Inc. (NASDAQ:NASDAQ:SWAV) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ETCompany ParticipantsDebbie Kaster - VP, IRDoug Godshall - President and CEOIsaac…
SANTA CLARA, Calif. (AP) — SANTA CLARA, Calif. (AP) — Shockwave Medical Inc. (SWAV) on Thursday reported fourth-quarter profit of…
ShockWave Medical press release (SWAV): Q4 GAAP EPS of $3.71 beats by $2.70.Revenue of $144M (+71.1% Y/Y) beats by $0.96M.Sees FY 2023 revenue to range from $660M…
SANTA CLARA, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV ), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2022. Recent Highlights Recognized revenue of $144.0 million for the fourth quarter of 2022 and $489.7 million for the full year 2022, representing increases of 71% and 107%, respectively, from the same periods in 2021 Received FDA approval for the Shockwave C 2 + Coronary IVL Catheter in the United States Granted increased reimbursement for the Shockwave C 2 Coronary IVL Catheter by the German INEK institute Entered into a definitive agreement to acquire Neovasc Inc. "We had a busy and successful fourth quarter, achieving record results across geographies and product lines. The team outperformed both operationally and strategically as we continue to advance our technology and our platform," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "2022 was another record year filled with significant accomplishments for Shockwave.
ShockWave Medical (SWAV) is scheduled to announce Q4 earnings results on Thursday, February 16th, after market close.The consensus EPS Estimate is $1.00 and the consensus Revenue…
ShockWave Medical (NASDAQ: SWAV ) is set to give its latest quarterly earnings report on Thursday, 2023-02-16. Here''s what investors need to know before the announcement. Analysts estimate that ShockWave Medical will report an earnings per share (EPS) of $1.00. ShockWave Medical bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
The share price of ShockWave Medical Inc. (NASDAQ:SWAV) fell to $189.49 per share on Thursday from $191.36. While ShockWave Medical Inc. has underperformed by -0.98%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 22.23%, with highs and lows ranging from $320.54 to $113.36, […]
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. Small-cap stocks posted solid returns in the fourth quarter for the first time in 2022. The Russell 2000 Growth Index was up 4.11% trailing the Russell 2000 […]
In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB ) climbed 6% so far this year. As a result, those who invest in pharma stocks now will benefit from the sector’s current positive momentum. But from my perspective, that’s just icing on the proverbial cake. The main reason to buy the shares of some pharma stocks is that the drugs that these firms have developed could eventually become huge blockbusters. And the stocks of the companies that accomplish that goal will produce huge returns. I like to recommend and buy pharma stocks whose products have not yet become blockbusters but have excellent chances because their risk-reward ratios are excellent. RVNC Revance’s $33.13 SWAV Shockwave $187.83 IMCR Immunocore $60.69 Revance (RVNC) Source: Roman Samborskyi / Shutterstock.com In September, the FDA approved Revance’s (NASDAQ: RVNC ) anti-frown line injection, DAXXIFY. Like Botox, the product is a neutrotoxin.